Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | Director | April 01, 2021 | April 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date April 01, 2021 · Filed April 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,700 |
Reported balance
After 2021-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-01 · Grant · Acquired 2,700 · Balance 2,700 F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2: The restricted stock units vest on April 1, 2022 and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.
F2: The restricted stock units vest on April 1, 2022 and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2021 Filed Apr 5, 2021 20:33 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 2,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-014835 · doc4.xml · derivative · entry 1 Parker David J · CIK 0001299047 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,700 Underlying: Class A Common Stock · 2,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on April 1, 2022 and have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest on April 1, 2022 and have no expiration date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 23:45 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006756 · doc4.xml · derivative · entry 1 Parker David J · CIK 0001299047 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Class A Common Stock · 9,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of BVS Class A Common Stock. F2 · derivative.exercise_date: 100% of the restricted stock units vest on 2/11/2022. F2 · derivative.expiration_date: 100% of the restricted stock units vest on 2/11/2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.